# Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

> **NCT04842019** · PHASE4 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- X-linked Hypophosphatemia (XLH)

## Interventions

- **DRUG:** KRN23

## Key facts

- **NCT ID:** NCT04842019
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2023-08-17
- **Final completion:** 2023-08-17
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842019, "Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04842019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*